Hostname: page-component-848d4c4894-wg55d Total loading time: 0 Render date: 2024-05-14T05:56:11.409Z Has data issue: false hasContentIssue false
  • English
  • Français

Atypical antipsychotics and neuroleptic malignant syndrome

Published online by Cambridge University Press:  03 January 2018

D. Kohen  and
M. F. Bristow
D. Kohen
Affiliation:
2nd Floor East Wing, Homerton Hospital, Homerton Row, London E9 6SR
M. F. Bristow
Affiliation:
Cheam Resource Centre, 671 London Road, North Cheam, Surrey SM3 9DL
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 175 , Issue 4 , October 1999 , pp. 392 - 393
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

References

Barnes, T. R. E. & McPhillips, M. A. (1999) Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. British Journal of Psychiatry, 174 (suppl. 38), 34–43.Google Scholar
Burkhard, P. R., Vingerhoets, F. J. G., Alberque, C., et of (1999) Olanzapine induced neuroleptic malignant syndrome. Archives of General Psychiatry, 56, 101–102.Google Scholar
Filice, G. A., McDougall, B. C., Ercan Fang, N., et al (1998) Neuroleptic malignant syndrome associated with olanzapine. Annals of Pharmacotherapy, 32, 1158–1159.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.